Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Resomelagon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resomelagon SCHEMBL31670337 | 1.00 | KMT2A (0.44) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| Resomelagon SCHEMBL29214577 | 0.94 | KMT2A (0.45) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| Resomelagon SCHEMBL30065234 | 0.94 | KMT2A (0.45) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| Resomelagon SCHEMBL30064288 | 0.94 | KMT2A (0.45) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| Resomelagon SCHEMBL12123977 | 0.94 | KMT2A (0.45) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| Resomelagon SCHEMBL29214576 | 0.94 | KMT2A (0.45) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| Resomelagon SCHEMBL29214574 | 0.94 | KMT2A (0.45) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| Resomelagon SCHEMBL31670336 | 0.92 | GRIN2D (0.41) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL26038037 | 0.90 | KMT2A (0.46) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| Acetic Acid SCHEMBL30064276 | 0.85 | KMT2A (0.42) | KMT2AL3MBTL1MAPTMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359076-B1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SYNACT PHARMA APS (DK) | 2025-08-06 | — | — | EP | claimed |
| WO-2025124760-A1 | TREATMENT OF SUBPOPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS | SYNACT PHARMA APS (DK) | 2025-06-19 | — | — | WO | claimed |
| EP-4359076-A1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SynAct Pharma ApS (DK) | 2024-05-01 | — | — | EP | claimed |
| CN-117642382-A | Phenylpyrrole aminoguanidine salts and formulations | 西奈克制药有限公司 | 2024-03-01 | — | — | CN | claimed |
| WO-2022268825-A1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SYNACT PHARMA APS (DK) | 2022-12-29 | — | — | WO | claimed |
| EP-4684835-A2 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SynAct Pharma ApS (DK) | 2026-01-28 | — | — | EP | disclosed |
| EP-4637921-A1 | POLYMORPH OF PHENYL PYRROLE HYDRAZINE CARBOXIMIDAMIDE COMPOUND | SynAct Pharma ApS (DK) | 2025-10-29 | — | — | EP | disclosed |
| EP-4359076-B1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SYNACT PHARMA APS (DK) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025124760-A1 | TREATMENT OF SUBPOPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS | SYNACT PHARMA APS (DK) | 2025-06-19 | — | — | WO | disclosed |
| US-12239631-B2 | Polymorphs of phenyl pyrrole aminoguandium salts | SYNACT PHARMA APS (DK) | 2025-03-04 | — | — | US | disclosed |
| US-20250032449-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | SYNACT PHARMA APS (DK) | 2025-01-30 | — | — | US | disclosed |
| US-20240335423-A1 | POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS | SYNACT PHARMA APS (DK) | 2024-10-10 | — | — | US | disclosed |
| CN-117836271-A | Salts of phenylpyrrolaminoguanidine and polymorphs of phenylpyrrolaminoguanidine onium salts | 西奈克制药有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117642382-A | Phenylpyrrole aminoguanidine salts and formulations | 西奈克制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230271922-A9 | POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS | SYNACT PHARMA APS (DK) | 2023-08-31 | — | — | US | disclosed |
| WO-2023094692-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | SYNACT PHARMA APS (DK) | 2023-06-01 | — | — | WO | disclosed |
| US-20230114865-A1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SYNACT PHARMA APS (DK) | 2023-04-13 | — | — | US | disclosed |
| US-20230002319-A1 | POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS | SYNACT PHARMA APS (DK) | 2023-01-05 | — | — | US | disclosed |
| WO-2022268825-A1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SYNACT PHARMA APS (DK) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022268814-A1 | SALTS OF PHENYL PYRROLE AMINOGUANIDINE AND POLYMORPHS OF PHENYL PYRROLE AMINOGUANIDINIUM SALTS | SYNACT PHARMA APS (DK) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032449-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | MTX1, MTX2, SYVN1 | KMT2A 3306/4885GRIN2D 3648/4885GRIN3B 2349/4885 |
| US-20230114865-A1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | AAAS, PGC, DNPEP | KMT2A 2093/4885GRIN2D 1823/4885GRIN3B 2232/4885 |
| US-20230271922-A9 | POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS | HLA-C, HLA-DRB1, HLA-B | KMT2A 4584/4885GRIN2D 2363/4885GRIN3B 2375/4885 |
| US-12239631-B2 | Polymorphs of phenyl pyrrole aminoguandium salts | HLA-C, HLA-DRB1, HLA-B | KMT2A 4584/4885GRIN2D 2363/4885GRIN3B 2375/4885 |
| US-20230002319-A1 | POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS | HLA-C, HLA-DRB1, HLA-B | KMT2A 4584/4885GRIN2D 2363/4885GRIN3B 2375/4885 |
| US-20240335423-A1 | POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS | HLA-C, HLA-DRB1, HLA-B | KMT2A 4584/4885GRIN2D 2363/4885GRIN3B 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.